Patent DE972682C successfully refreshed from Google Patents.
EP0555880A2
Expired / Lapsed
EP
⏱️ 0.0 years remaining
The CD40CR receptor and ligands therefor
Assignee: Dartmouth College
•
Filing: 1993-02-12
•
Granted: —
•
Expires: 2013-02-12
Abstract
Abstract The present invention relates to a counter-receptor, termed CD40CR, for the CD40 B-cell antigen, and to soluble ligands for this receptor, including fusion molecules comprising at least a portion of CD40 protein. It is based, at least in part, on the discovery that a soluble CD40/immunoglobulin fusion protein was able to inhibit helper T-cell mediated B-cell activation by binding to a novel 39 kD protein receptor on helper T-cell membranes. The present invention provides for a substantially purified CD40CR receptor; for soluble ligands of CD40CR, including antibodies as well as fusion molecules comprising at least a portion of CD40 protein; and for methods of controlling B-cell activation which may be especially useful in the treatment of allergy or autoimmune disease.
Inventors
- 👤 Alejandro A. Aruffo
- 👤 Jeffrey A. Ledbetter
- 👤 Randolph Noell
- 👤 Ivan Stamenkovic
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-11-03 17:53
CPC Classifications
C; C07; C07K; C07K16/00; C07K16/18; C07K16/28; C07K16/2875; C07K14/00; C07K14/435; C07K14/705; C07K14/70578; A; A61; A61P; A61P17/00; A61P31/00; A61P31/12; A61P31/14; A61P31/18; A61P37/00; A61P37/02; A61P37/06; A61P37/08; C07K14/70575; A61K; A61K39/00; A61K2039/505; A61K38/00; C07K2317/00; C07K2317/50; C07K2317/52; C07K2317/524; C07K2317/526; C07K2317/70; C07K2317/73; C07K2317/76; C07K2319/00; C07K2319/01; C07K2319/03; Y; Y10; Y10S; Y10S530/00; Y10S530/866; Y10S530/868
Claims Analysis
Total Claims: 23
Claim 1
Independent Claim
5 words
A substantially purified CD40CR receptor.
Claim 2
Dependent Claim
16 words
The substantially purified receptor of claim 1 which has a molecular weight of about 39 kilodaltons.
Claim 3
Dependent Claim
11 words
The substantially purified receptor of claim 1 which binds to CD40-Ig.
Claim 4
Dependent Claim
14 words
The substantially purified receptor of claim 1 which binds to the monoclonal antibody MR1.
Claim 5
Dependent Claim
13 words
A soluble ligand for CD40CR, comprising at least a portion of CD40 protein.
Claim 6
Dependent Claim
18 words
The soluble ligand of claim 5 which comprises a portion of CD40 protein which lacks a transmembrane domain.
Claim 7
Dependent Claim
19 words
The soluble ligand of claim 5 or 6 which further comprises at least a portion of an immunoglobulin molecule.
Claim 8
Dependent Claim
9 words
The soluble ligand of claim 5 which is CD40-Ig.
Claim 9
Dependent Claim
14 words
A soluble ligand for CD40CR, comprising at least a portion of an immunoglobulin molecule.
Claim 10
Dependent Claim
22 words
The soluble ligand of claim 9 in which the immunoglobulin molecule is capable of competitively inhibiting the binding of CD40 to CD40CR.
Claim 11
Dependent Claim
26 words
The soluble ligand of claim 9 in which the immunoglobulin molecule is capable of competitively inhibiting the binding of monoclonal antibody MR1 to its target antigen.
Claim 12
Dependent Claim
49 words
The soluble ligand according to claim 9, 10 or 11 which further comprises a second molecule which is selected from the group consisting of an antiproliferative agent, an alkylating agent, an antimetabolite, an antibiotic, a vinca alkaloid, an enzyme, a platinum coordinated complex, a radioisotope, or a fluorescent compound.
Claim 13
Dependent Claim
24 words
Monoclonal antibody MR1 produced by a hybridoma cell line as deposited with the ATCC and assigned accession number HB 11048 or a fragment thereof.
Claim 14
Independent Claim
28 words
A method of inhibiting B-cell activation in vitro comprising exposing a mixture of B-cells and helper T cells to an effective concentration of ligand that binds to CD40CR.
Claim 15
Dependent Claim
20 words
The method of claim 14 wherein a ligand as defined in one of the claims 5 to 12 is applied.
Claim 16
Dependent Claim
18 words
The use of a ligand that binds to CD40CR for preparing a pharmaceutical composition for inhibiting B-cell activation.
Claim 17
Dependent Claim
20 words
The use of claim 16 wherein a ligand as defined in one of the claims 5 to 12 is applied.
Claim 18
Dependent Claim
26 words
The use of a ligand that binds to CD40CR for preparing a pharmaceutical composition for treating a subject suffering from a disorder associated with B-cell activation.
Claim 19
Dependent Claim
16 words
The use of claim 18 in which the disorder is an allergy or an autoimmune disease.
Claim 20
Dependent Claim
20 words
The use of claim 18 in which the ligand is as defined in one of the claims 5 to 12.
Claim 21
Dependent Claim
10 words
A pharmaceutical composition comprising CD40-Ig in a suitable pharmaceutical carrier.
Claim 22
Dependent Claim
16 words
A pharmaceutical composition comprising monoclonal antibody MR1 or a fragment thereof in a suitable pharmaceutical carrier.
Claim 23
Dependent Claim
14 words
Hybridoma cell line as deposited with the ATCC and assigned accession number HB 11048.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.